Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjects

Journal of Infectious Diseases

Volumn 206, Issue 7, 2012, Pages 1002-1011

  Nettles, Richard E ^a,e   Schürmann, Dirk ^c   Zhu, Li ^a   Stonier, Michele ^a   Huang, Shu Pang ^a   Chang, Ih ^a   Chien, Caly ^a,d   Krystal, Mark ^b   Wind Rotolo, Megan ^a   Ray, Neelanjana ^a   Hanna, George J ^a   Bertz, Richard ^a   Grasela, Dennis ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b BMS   (United States)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d JOHNSON AND JOHNSON   (United States)

^e JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; BMS 626529; BMS 663068; GLYCOPROTEIN GP 120; RITONAVIR; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; AREA UNDER THE CURVE; BEDTIME DOSAGE; CD4+ T LYMPHOCYTE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; MAJOR CLINICAL STUDY; MALE; MICTURITION DISORDER; MINIMUM INHIBITORY CONCENTRATION; MORNING DOSAGE; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEADY STATE; VIRUS ATTACHMENT; VIRUS LOAD;

ADULT; AGED; AREA UNDER CURVE; DRUG THERAPY, COMBINATION; FEMALE; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INHIBITORY CONCENTRATION 50; MALE; MIDDLE AGED; ORGANOPHOSPHATES; PIPERAZINES; RITONAVIR; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84866124136     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis432     Document Type: Conference Paper

References (12)

1. Adamson CS, Freed EO. Novel approaches to inhibiting HIV-1 replication. Antiviral Res 2010; 85:119-41.
2. Bhattacharya S, Osman H. Novel targets for anti-retroviral therapy. J Infect 2009; 59:377-86.
3. Kuritzkes DR. HIV-1 entry inhibitors: an overview. Curr Opin HIV AIDS 2009; 4:82-7.
4. Tilton JC, Doms RW. Entry inhibitors in the treatment of HIV-1 infection. Antiviral Res 2010; 85:91-100.
5. Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003; 348:2175-85. (Pubitemid 36618128)
6. Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008; 359:1429-41.
7. Hanna GJ, Lalezari J, Hellinger JA, et al. Antiviral activity, pharmaco-kinetics, and safety of BMS-488043, a novel oral small-molecule HIV-1 attachment inhibitor, in HIV-1-infected subjects. Antimicrob Agents Chemother 2011; 55:722-8.
8. Nowicka-Sans B, Gong YF, McAuliffe B, et al. In vitro antiviral characteristics of HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068. Antimicrob Agents Chemother 2011; 56:3498-507.
9. Wang T, Ueda Y, Connolly TP, et al. Use of a phosphonoxymethyl prodrug approach to successfully improve the oral delivery of HIV-1 attachment inhibitors: design, preclinical profile, and human exposure [abstract MEDI-346]. Presented at: 239th American Chemical Society National Meeting, San Francisco, CA, 21-25 March 2010.
10. Nettles R, Chien C, Elefant E, et al. Single and multiple dose pharma-cokinetics and safety in non-HIV-infected healthy subjects dosed with BMS-663068, an oral HIV attachment inhibitor [abstract O-04]. Presented at: 12th International Workshop on Clinical Pharmacology of HIV Therapy, Miami, FL, 13-15 April 2011.
11. Markowitz M, Morales-Ramirez JO, Nguyen BY, et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr 2006; 43:509-15. (Pubitemid 44885615)
12. Min S, Sloan L, DeJesus E, et al. Antiviral activity, safety, and pharma-cokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults. AIDS 2011; 25:1737-45.